Seroprevalence of Antitransglutaminase and Antiendomysium Antibodies in Adult Colombian Blood Bank Donors

الملخص EN

Celiac disease (CD) is an autoimmune enteropathy induced by the ingestion of gluten from wheat, barley, and rye in genetically susceptible individuals.

The global prevalence of CD is 1.4%.

However, most of the prevalence studies have been conducted in Caucasian populations; few studies have been performed in Latin America.

The aim of this study is to determine the seroprevalence of auto-antibodies used as markers for CD in a Colombian cohort.

In this cross-sectional study, the serum samples from Colombian donors of the National Red Cross Blood Bank were collected between June and September 2017 in Bogotá, Colombia.

All sera were tested for IgA antitissue transglutaminase (TTG) by enzyme-linked immunosorbent assay.

Seropositive sera were tested for IgA antiendomysium (EMA) using indirect immunofluorescence assay.

The ancestral genetic composition was determined in donor samples with antibody assay reactivity.

Those with two seroreactive assays were typed for HLA class II DQ2 and DQ8.

In total, 228 blood donors participated in the study.

Among them, 113 were females (49.56%) with an average age of 31.63 years (SD ± 12.99); males had an average of 34.71 years (SD ± 13.01).

Only 3 (1.31%) donors reported chronic diarrhea and nonintentional weight loss; 11 (4.82%) had a family history of CD.

For the serological assays, 11 donors (4.82%) were seroreactive to IgA anti-TTG: 3 had high reactivity and 8 had low reactivity.

Of those seroreactive to IgA anti-TTG, 3 (1.32%) were also seroreactive to anti-EMA, and they were typed as HLA-DQ8 or HLA-DQ2.

The baseline ancestral percentage of the seroreactive donors was higher for European and Native American than for African genes.

The seroprevalence for anti-TTG and anti-EMA with the presence of HLA-DQ8 and HLA-DQ2 was 1.32%.

Additionally, 4.82% donor participants were reactive only for anti-TTG.

Compared with other studies, our findings suggest that Colombia has a high prevalence of CD markers.